Aflibercept in pediatric solid tumors: Moving beyond the trap

Cindy H. Chau; William D. Figg

doi:10.1158/1078-0432.CCR-12-2212

Aflibercept in pediatric solid tumors: Moving beyond the trap

Cindy H. Chau, William D. Figg^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Angiogenesis plays a pivotal role in the growth and metastasis of adult and pediatric solid tumors. Clinical investigation of angiogenesis inhibitors is currently under way for childhood cancers. While the pediatric study of aflibercept provides a proof-of-principle, challenges remain in developing clinical endpoints and biomarkers of angiogenesis for pediatric trials.

Original language	English
Pages (from-to)	4868-4871
Number of pages	4
Journal	Clinical Cancer Research
Volume	18
Issue number	18
DOIs	https://doi.org/10.1158/1078-0432.CCR-12-2212
State	Published - 15 Sep 2012
Externally published	Yes

Access to Document

10.1158/1078-0432.CCR-12-2212

Cite this

@article{a95016da6f5445c3b070152944a97a7f,

title = "Aflibercept in pediatric solid tumors: Moving beyond the trap",

abstract = "Angiogenesis plays a pivotal role in the growth and metastasis of adult and pediatric solid tumors. Clinical investigation of angiogenesis inhibitors is currently under way for childhood cancers. While the pediatric study of aflibercept provides a proof-of-principle, challenges remain in developing clinical endpoints and biomarkers of angiogenesis for pediatric trials.",

author = "Chau, {Cindy H.} and Figg, {William D.}",

year = "2012",

month = sep,

day = "15",

doi = "10.1158/1078-0432.CCR-12-2212",

language = "English",

volume = "18",

pages = "4868--4871",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "18",

}

TY - JOUR

T1 - Aflibercept in pediatric solid tumors

T2 - Moving beyond the trap

AU - Chau, Cindy H.

AU - Figg, William D.

PY - 2012/9/15

Y1 - 2012/9/15

N2 - Angiogenesis plays a pivotal role in the growth and metastasis of adult and pediatric solid tumors. Clinical investigation of angiogenesis inhibitors is currently under way for childhood cancers. While the pediatric study of aflibercept provides a proof-of-principle, challenges remain in developing clinical endpoints and biomarkers of angiogenesis for pediatric trials.

AB - Angiogenesis plays a pivotal role in the growth and metastasis of adult and pediatric solid tumors. Clinical investigation of angiogenesis inhibitors is currently under way for childhood cancers. While the pediatric study of aflibercept provides a proof-of-principle, challenges remain in developing clinical endpoints and biomarkers of angiogenesis for pediatric trials.

UR - http://www.scopus.com/inward/record.url?scp=84866412364&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-2212

DO - 10.1158/1078-0432.CCR-12-2212

M3 - Article

C2 - 22869868

AN - SCOPUS:84866412364

SN - 1078-0432

VL - 18

SP - 4868

EP - 4871

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 18

ER -

Aflibercept in pediatric solid tumors: Moving beyond the trap

Abstract

Access to Document

Fingerprint

Cite this